In this setting, blocking the binding of PD1 on T-cells to PDL1 on tumor cells using checkpoint inhibitors, such as pembrolizumab, an anti-PD1 antibody, causes T-cell activation and targeting of tumor cells and the tumor microenvironment [56]. This evidence concerns the gene CD274 and neoplasm.